SAB BIO continues to execute its corporate strategy through building partnerships and expertise that advances our focus on immunotherapy, specifically type 1 diabetes (T1D).  

In May 2024, the U.S. Food and Drug Administration (FDA) provided clearance on the investigational new drug (IND) application to proceed with the phase 1 clinical trial for type 1 diabetes therapy SAB-142 in the United States. 

Phase 1 data from an ongoing clinical trial in Australia for SAB-142 are expected by the end of 2024 with a goal of demonstrating a best-in-class therapeutic profile for the prevention and disease modification of T1D. 

In addition to SAB-142, SAB BIO has clinical-stage assets to treat infectious diseases that have significant mortality and morbidity in the general population and in high-risk patients. 

While our autoimmunity pipeline is currently focused on developing a disease-modifying therapy for type 1 diabetes, we look to utilize our platform in autoimmunity more broadly with additional details to come.